Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet

Core Insights - Aclarion, Inc. is participating in the 38th Annual ROTH Conference from March 22-24, 2026, to discuss its proprietary MR spectroscopy platform, Nociscan, aimed at identifying chronic low back pain [1][2] Company Overview - Aclarion is a commercial-stage healthcare technology company utilizing biomarkers and augmented intelligence algorithms to assist physicians in diagnosing chronic low back pain [1][4] - The company’s Nociscan platform is the first evidence-supported SaaS solution designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine [4] Financial Position - Aclarion has a strong balance sheet with no debt, positioning the company well for future growth and expansion of Nociscan in both the UK and US markets [3] Conference Engagement - CEO Brent Ness will hold one-on-one meetings with institutional investors and analysts during the ROTH Conference to discuss the company's advancements and future catalysts [2][3]